Management of Popliteal Sentinel Nodes in Melanoma - 10/08/11
Résumé |
Background |
Although most melanomas on the distal lower extremity drain exclusively to inguinal lymph nodes, a small percentage (<5%) drain to interval nodes in the popliteal basin. We investigated a possible relationship between tumor-draining popliteal and inguinal nodes in patients with lower-extremity melanoma.
Study Design |
We queried our melanoma database to identify patients who underwent sentinel node biopsy (SNB) for an infrapopliteal melanoma. Patterns of nodal drainage and nodal metastasis were analyzed.
Results |
Of 461 patients who underwent SNB for a primary infrapopliteal melanoma, 15 (3.2%) had drainage to the popliteal basin. Thirteen melanomas were on the posterior leg and foot, and 2 were on the anterior lower leg. Mean Breslow thickness was 2.4 mm. All 15 patients with popliteal drainage also had inguinal drainage and therefore underwent concurrent inguinal and popliteal SNB. The average number of popliteal sentinel nodes was 1.4 (range 1 to 3). Eight patients (53%) had a tumor-positive popliteal sentinel node, and 6 of the 8 underwent completion popliteal lymphadenectomy. Four of the 8 patients (50%) also had tumor-positive inguinal sentinel nodes; all underwent complete inguinal lymphadenectomy. We also identified 9 additional patients who underwent SNB for locoregional recurrent melanomas of the infrapopliteal leg. Three (33%) of these patients had concurrent inguinal and popliteal SNB, with 1 isolated tumor-positive popliteal node found.
Conclusions |
In our series, a high percentage of popliteal sentinel lymph nodes contained metastases, and these patients frequently also had inguinal metastases. In our patients, all inguinal metastases were associated with concomitant popliteal metastases. Although it is anatomically separate, the inguinal basin appears to be a functional extension of the popliteal basin.
Le texte complet de cet article est disponible en PDF.Plan
Author Disclosure Information: Nothing to disclose. Editor Disclosure Information: Nothing to disclose. |
|
Supported by grants P01 CA29605 and P01 CA12582 from the National Cancer Institute and by funding from the Melanoma Research Alliance (Washington, DC), Dr Miriam & Sheldon G Adelson Medical Research Foundation (Boston, MA), the Lincy Foundation (Beverly Hills, CA), the Amyx Foundation, Inc (Boise, ID), Alan and Brenda Borstein (Los Angeles, CA), Mr and Mrs Louis Johnson (Stanfield, AZ), Heather and Jim Murren (Las Vegas, NV), the Wayne and Gladys Valley Foundation (Oakland, CA), the Lance Armstrong Foundation (Austin, TX), the Samueli Foundation (Corona del Mar, CA), the John Wayne Cancer Foundation (Newport Beach, CA), and the Wrather Family Foundation (Los Alamos, CA). Dr Steen is the Carolyn Dirks Fellow (Los Angeles, CA). The content is solely the responsibility of the authors and does not necessarily represent the official view of the National Cancer Institute or the National Institutes of Health. |
Vol 213 - N° 1
P. 180-186 - juillet 2011 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?